BLUEFIELD REGIONAL MEDICAL CENTER

Br. 1

January

U.S.N.R.C.
Region I
2100 Renaissance BLVD
King of Prussia, PA 19406

To Whom It May Concern,

Re: License Number 47-19142-01 03017038

Please amend our radioactive materials license as follows:

1. Add Steven J. Yousko, MD as an authorized user for materials identified in 10 CFR 35.100 and 35.200. Dr. Yousko is identified as an authorized user for the same materials on the State of Arizona radioactive materials license for Verde Valley Medical Center license # 13-007. A copy of this document is attached for reference.

Thank you for your attention to this matter.

Sincerely,

GiGi Fergus
CEO

590206

500 CHERRY STREET • BLUEFIELD, WEST VIRGINIA, 24701 • (304) 327-1100

ARRA-3

ARIZONA RADIATION REGULATORY AGENCY

RADIOACTIVE MATERIAL LICENSE

Pursuant to Chapter 4, Title 30, Arizona Revised Statutes, and Title 12, Chapter 1 of the Arizona Administrative Code, and in reliance on statements and representations made to the Agency by the licensee, a license is hereby issued authorizing the acquisition, reception, possession, use and transfer of the radioactive material listed in this license for the purposes and at the places specified. This license is subject to all applicable rules and Agency orders now or hereafter in effect and to the conditions specified. In accordance with letter dated December 26, 2013, signed by Frank Rafie, License Number 13-007 is hereby amended in its entirety to read as follows: **ALL CHANGES ARE IN BOLD**

LICENSEE

1. **NAME:** Verde Valley Medical Center
2. **ADDRESS:** 269 South Candy Lane
   Cottonwood, Arizona 86326

3. a. **LICENSE NUMBER:** 13-007
   b. **AMENDMENT NO.:** 42
4. **EXPIRATION DATE:** February 28, 2017
5. **CATEGORY:** B2 (2) - MEDICAL MATERIALS. CLASS B

6. Radioactive material (element and mass number)	7. Chemical or physical form	8. Maximum quantity licensee may possess at any time
A. Any radioactive material listed in Group 100 of Exhibit A, Arizona Administrative Code, Title 12, Chapter 1, Article 7	A. Any **FDA approved** radiopharmaceutical authorized in Group 100 of Exhibit A, Arizona Administrative Code, Title 12, Chapter 1, Article 7. **Not to include investigational new drugs (IND).**	A. 37GBq (1,000 millicuries)
B. Any radioactive material listed in Group 200 of Exhibit A, Arizona Administrative Code, Title 12, Chapter 1, Article 7	B. Any **FDA approved** radiopharmaceutical authorized in Group 200 of Exhibit A, Arizona Administrative Code, Title 12, Chapter 1, Article 7. **Not to include investigational new drugs (IND).**	B. 74 GBq (2 curies)
C. Xenon-133	C. Gas or gas in saline	C. 3.7 GBq (100 millicuries)
D. Iodine-125	D. Sealed Source	D. 18.5 GBq (500 millicuries)
E. Iridium-192	E. Sealed Source	E. 2 sources total, not to exceed 740 GBq (20 curies)

9. **Authorized Use:**

   A. For certain diagnostic studies involving measurements of uptake, dilution and excretion authorized in Group 100 of Exhibit A, Arizona Administrative Code, Title 12, Chapter 1, Article 7.

POST IN ACCORDANCE WITH R12-1-1002

ARIZONA RADIATION REGULATORY AGENCY

RADIOACTIVE MATERIAL LICENSE
SUPPLEMENTARY SHEET

License Number: 13-007
Amendment Number: 42

B. For certain diagnostic studies involving imaging and tumor localizations authorized in Group 200 of Exhibit A, Arizona Administrative Code, Title 12, Chapter 1, Article 7.

C. For blood flow and pulmonary function studies.

D. For interstitial treatment of cancer.

E. For use in Varian Gamma Medplus ix, HDR, for the interstitial intraluminal and intracavitary treatment of cancer.

CONDITIONS

10. A. Radioactive material listed under sub items A through D of items 6, 7 and 8 may be possessed and used at the licensee's address stated in Item 2 above and at 294 West Highway 89 A, Suite 107, on the VVMC Campus.

B. Radioactive material listed under sub item E of Items 6, 7 and 8 may be possessed and used at 3700 West State Route 89A, Sedona, Arizona 86996.

11. The licensee shall comply with the provisions of Title 12, Chapter 1, Arizona Administrative Code; Article 3, "Radioactive Material Licensing"; Article 4, "Standards for Protection Against Ionizing Radiation"; Article 7, "Medical Uses of Radioactive Material"; and Article 10, "Notices, Instructions and Reports to Ionizing Radiation Workers; Inspections".

12. A. Radioactive materials listed in subitems A through C of items 6, 7 and 8 above, shall be used by, or under the supervision of:

Robert W. Koepke, M.D. Frank D. Matthews, M.D. Warren L. Mays, M.D.

Alan D. Wilson, M.D. Steven J. Yousko, M.D.

B. Radioactive material listed in subitem D of items 6, 7 and 8 above, shall be used by, or under the supervision of: Andrew K. David, M.D.

C. **Radioactive material listed in sub item E of Items 6, 7 and 8 above, shall be used by or under the supervision of:**

David Beyer, M.D. Heyong McBride, M.D. Emad Youssef, M.D.

D. The authorized medical physicists for this license are:

Frank Rafie **Gregory Dominiak, M.S.**

E. The Radiation Safety Officer for this license is: Frank Rafie.

F. The Alternate Radiation Safety Officer is: Salvatore Moribito. The Alternate Radiation Safety Officer shall administer the Radiation Safety Program under the policy and procedure guidance of the Radiation Safety Officer.

POST IN ACCORDANCE WITH R12-1-1002

ARIZONA RADIATION REGULATORY AGENCY

RADIOACTIVE MATERIAL LICENSE

SUPPLEMENTARY SHEET

License Number: 13-007
Amendment Number: 42

13. The licensee shall perform a semiannual airflow direction check to verify a negative pressure differential within the Nuclear Medicine Department relative to surrounding areas. The licensee shall also perform annual ventilation flow rate measurements within the Department to ensure that radioactive gases in use are properly diluted and exhausted.

14. **The licensee is authorized to release a patient in accordance with R12-1-717, in addition to the following conditions:**

    A. **A patient may be released from licensee control without concern, if the activity administered is no greater than the activity in Column 1 of Table (U)(1) of NUREG 1556, Volume 9, Rev 2, available on the NRC website. The licensee shall maintain a record of the release in accordance with R12-1-717. A patient shall be given instruction as required in Part E below.**

    B. **A patient may be released from licensee control if administered an activity amount greater than the activities in Part A above, provided the measured dose rate at 1 meter from the surface of the patient is no greater than the value in Column 2 of Table (U)(1), for the radionuclide administered to the patient. In addition to the record requirements in Part A above, the licensee shall survey the patient before release and record the reading, survey instrument used, and person performing the survey, as described in Section (U)(3)(1), NUREG 1556. A patient shall be given instructions, as required in Part E below.**

    C. **If a licensee chooses to administer a radionuclide (i.e. Cs-131) not listed in Table (U)(1) and release the patient based on the measured dose rate, the licensee shall calculate the dose rate that corresponds to the 500 mRem dose limit, using the suggested method in Section (U)(1)(2) of NREG 1556. If the measured dose rate is no greater than the calculated dose rate the patient may be released in accordance with Part B above. A patient shall be given instructions, as required in Part E below.**

    D. **In lieu of the surveys required by this license condition, a licensee may perform a dose calculation using patient specific parameters in accordance with section (U)(1)(3) of NUREG 1556.**

    E. **As applicable, the licensee shall provide the patient instructions in accordance with Section (U)(2)(3)(1) or (U)(2)(3)(2), NUREG 1556.**

15. The licensee shall not use F-18 radiopharmaceuticals until the Agency has approved the licensee's procedures, equipment, and facilities for its use, and amended this license for F-18 use.

16. For purposes of ending the principal activities authorized under this radioactive material license:

    A. The license stays in effect beyond the license expiration date. Beyond the expiration date the licensee shall store radioactive material only, until the Agency authorizes its use by license amendment, or the Agency notifies the licensee in writing that the license is terminated.

    B. The licensee shall ensure the timeliness of decommissioning of facilities where principal activities are conducted under this license in accordance with Agency requirements.

    C. The licensee shall continue to control public access into restricted areas and pay the annual licensing fee until the license is terminated.

17. The licensee shall ensure that each high dose rate remote afterloader unit is used in accordance with R12-1-732 (A) through (E) and supervised in accordance with subsection (F)(2).

ARRA-3 (Cont.)

ARIZONA RADIATION REGULATORY AGENCY

RADIOACTIVE MATERIAL LICENSE

SUPPLEMENTARY SHEET

License Number: 13-007
Amendment Number: 42

18. In accordance with R12-1-708, the licensee shall ensure the dose and source positioning inputted into the HDR therapy system are in agreement with an authorized user's written directive

19. Except as specifically provided otherwise by this license, the licensee shall possess and use the radioactive material described in Items 6, 7 and 8 of this license in accordance with the statements, representations and procedures contained in:

    1. Application dated February 8, 2012, signed by James Bleicher.

    2. Letters with attachments dated November 15, 2011, signed by Salvatore Morabito and January 25, 2012, signed by Elizabeth Palomino.

The most recent statements, representations, and procedures shall govern if they conflict with previously submitted documents, unless otherwise specified by a license condition; and the Agency's rules shall govern the licensee's statements in applications or letters.

AUBREY V. GODWIN, DIRECTOR

PRK:AVG:hlh

DATE ISSUED: JAN 1 3 2014

POST IN ACCORDANCE WITH R12-1-1002

This is to acknowledge the receipt of your letter/application ~~dated~~ received 02/08/16, and to inform you that the initial processing which includes an administrative review has been performed.

Amendment (47-19142-01)

☒ There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 590206.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (RI)
(6-96)

Sincerely,
Licensing Assistance Team Leader